Literature DB >> 7475768

Prospective screening of dyspeptic patients by Helicobacter pylori serology.

P Patel1, S Khulusi, M A Mendall, R Lloyd, R Jazrawi, J D Maxwell, T C Northfield.   

Abstract

Helicobacter pylori infection is associated with 95% of duodenal ulcers and more than 80% of gastric ulcers. Several reports have indicated that screening for H pylori may avoid subsequent endoscopic examination. We screened 183 dyspeptic patients, aged under 45, by taking a history of sinister symptoms and regular use of non-steroidal anti-inflammatory drugs (NSAIDs), together with serological testing for H pylori. Endoscopy was performed on 113 patients, of whom 90 (49%) were seropositive, 14 (8%) had sinister symptoms, and 9 (5%) had used NSAIDs regularly. In 34 (19%) patients we detected peptic ulceration. The remaining 70 (38%) patients who were H pylori seronegative, had no sinister symptoms, and had not taken NSAIDs (screen-negative), did not undergo endoscopy but were returned to their primary care physician for treatment of symptoms. At subsequent reassessment (of the non-endoscoped group), symptom severity (p = 0.002), interference with life events (p = 0.01), and medication (p = 0.0002) were all significantly lower in the 6 months after screening than in the 6 month period before screening. Only three screen-negative patients were re-referred after screening but their endoscopic findings were normal. Thus, 67 (36%) endoscopies were avoided. When the non-endoscoped screen-negative patients were compared with a cohort of endoscoped screen-negative patients, the groups did not differ in terms of symptom severity (odds ratio 1.12, 95% CI 0.53-2.35, p = 0.77) or interference with life events (0.82, 0.38-1.76, p-0.61). However, medication use was significantly less (0.37, 0.17-0.80, p = 0.01) in those who did not have an endoscopy. Our study indicates that colonisation screening based on H pylori serology, a history of sinister symptoms, or a history of NSAID use was worthwhile in dyspeptic patients. We avoided 37% of endoscopies and reduced drug usage without disadvantaging those not endoscoped.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7475768     DOI: 10.1016/s0140-6736(95)92340-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  41 in total

Review 1.  ACP. Best practice no 154. February 1999. Helicobacter pylori.

Authors:  C A McNulty; J I Wyatt
Journal:  J Clin Pathol       Date:  1999-05       Impact factor: 3.411

Review 2.  Management of upper gastrointestinal cancers.

Authors:  A Melville; E Morris; D Forman; A Eastwood
Journal:  Qual Health Care       Date:  2001-03

3.  Helicobacter pylori infection.

Authors:  Yvan Vandenplas
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

4.  [Failure of rapid serology for Helicobacter pylori as diagnostic method in primary care consultation].

Authors:  L M Valle; J Valdepérez; M Tirado; D Verduras; C Yus; F Gomollón
Journal:  Aten Primaria       Date:  2001-06-30       Impact factor: 1.137

Review 5.  Approaches to uninvestigated dyspepsia.

Authors:  R H Jones
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 6.  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

Authors: 
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

7.  The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients.

Authors:  K E McColl; A el-Nujumi; L Murray; E el-Omar; D Gillen; A Dickson; A Kelman; T E Hilditch
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

Review 8.  How should Helicobacter pylori negative patients be managed?

Authors:  V Stanghellini; C Tosetti; R De Giorgio; G Barbara; B Salvioli; R Corinaldesi
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 9.  How should Helicobacter pylori positive dyspeptic patients be managed?

Authors:  N J Talley
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

10.  Clinical significance of Helicobacter pylori seropositivity and seronegativity in asymptomatic blood donors.

Authors:  M Menegatti; J Holton; N Figura; G Biasco; C Ricci; G Oderda; R Conte; M Miglioli; D Vaira
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.